Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism
Autor: | Giovanni Fabbri, Laura Maria Beatrice Belotti, Giovanna Calandra-Buonaura, Carlo Descovich, Susanna Trombetti, Corrado Zenesini, Francesco Nonino, Roberta Pantieri, Luca Vignatelli, Cesa Scaglione, Giuseppe Samoggia, Giuseppe Bonavina, Elisa Baldin, Roberto D'Alessandro, Giulia Giannini, Maria Guarino, Pietro Cortelli |
---|---|
Přispěvatelé: | Vignatelli, Luca, Zenesini, Corrado, Belotti, Laura M B, Baldin, Elisa, Bonavina, Giuseppe, Calandra-Buonaura, Giovanna, Cortelli, Pietro, Descovich, Carlo, Fabbri, Giovanni, Giannini, Giulia, Guarino, Maria, Pantieri, Roberta, Samoggia, Giuseppe, Scaglione, Cesa, Trombetti, Susanna, D'Alessandro, Roberto, Nonino, Francesco |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Adult
Male Risk 0301 basic medicine medicine.medical_specialty Parkinson's disease Clinical Neurology Cohort Studies 03 medical and health sciences Patient Admission 0302 clinical medicine Parkinsonian Disorders COVID‐19 Internal medicine Case fatality rate Humans Medicine Risk factor Research Articles parkinsonism Aged Aged 80 and over business.industry Mortality rate Parkinsonism Hazard ratio COVID-19 Parkinson Disease Length of Stay Middle Aged medicine.disease frail elderly Nursing Homes nervous system diseases Hospitalization 030104 developmental biology Italy Neurology Cohort Female Neurology (clinical) business 030217 neurology & neurosurgery Research Article Cohort study cohort studie |
Zdroj: | Movement Disorders |
Popis: | Background The risk of COVID‐19 and related death in people with Parkinson's disease or parkinsonism is uncertain. The aim of the study was to assess the risk of hospitalization for COVID‐19 and death in a cohort of patients with Parkinson's disease or parkinsonism compared with a control population cohort, during the epidemic bout (March–May 2020) in Bologna, northern Italy. Methods Participants of the ParkLink study with the clinical diagnosis of Parkinson's disease or parkinsonism and people anonymously matched (ratio 1:10) for sex, age, district, and Charlson Index were included. The hospital admission rate for COVID‐19 (February 26–May 31, 2020) and the death rate for any cause were the outcomes of interest. Results The ParkLink cohort included 696 subjects with Parkinson's disease and 184 with parkinsonism, and the control cohort had 8590 subjects. The 3‐month hospitalization rate for COVID‐19 was 0.6% in Parkinson's disease, 3.3% in parkinsonism, and 0.7% in controls. The adjusted hazard ratio (age, sex, district, Charlson Index) was 0.8 (95% CI, 0.3–2.3, P = 0.74) in Parkinson's disease and 3.3 (1.4–7.6, P = 0.006) in parkinsonism compared with controls. Twenty‐nine of the infected subjects died; 30‐day fatality rate was 35.1%, without difference among the 3 groups. Six of 10 Parkinson's disease/parkinsonism patients had the infection during hospitalization or in a nursing home. Conclusions Parkinson's disease per se probably is not a risk factor for COVID‐19 hospitalization. Conversely, parkinsonism is an independent risk factor probably because of a more severe health status, entailing higher care dependence and placement in high‐infection‐risk accommodations. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society. |
Databáze: | OpenAIRE |
Externí odkaz: |